Innovus Pharma (INNV) On the Verge of Breakin
Post# of 99212
Posted On: 08/27/2016 7:50:02 PM
Innovus Pharma (INNV)
On the Verge of Breaking Through:
What we Know:
- Tracking at $5M in revs for 2016(At a loss for words if they fall short)
- 3 new products being launched in 2016 (they are coming)
- Fluticare's FDA decision expected by end of Sept. (FDA, step it up)
- New Asian Deal Signed (Done deal)
- New Deal with India signed / KLABs contracted (Done Deal)
- Beyond Human Product sales Increasing YOY (Done Deal)
- Dr. Damaj is not taking actual money / pay for the rest of this year
- Enough cash on hand to fund Operations through Q3 of 2017
- Lots of warrants at an exercise price of 40 cents out there
What is Expected:
- A fair amount of short covering should FDA approval hit
- $2.5 - 3M total from recent signings of the Asian and Indian deals
- $4M/annually from those 3 new products alone
- Fluticare approval brings $13-14M in USA sales (in first Full year)
- Int'l Fluticare approval EVENTUALLY brings in $10-11M overseas
- Continued launches of existing products in more countries
- Profitability in Q2 or Q3 of 2017
- Uplisting to a better exchange
- Continued Rev growth for BH products and Vesele / cross sales
- Same or better margins (online sales have a lot nicer margins)
- Eventual buyout sometime in 2018/2019
What is Unknown:
- How does their increased exposure / customer base affect sales?
- Will they continue to make solid acquisitions?
- Will the number of and royalties from even more distribution deals happen soon?
- Will they ever do a reverse split ?
- Would Dr. Damaj ever give back some of his personal shares to the Treasury in an effort to INCREASE PPS and DECREASE O/S?
- How do they key in on & improve Marketing, inside and outside of USA ?
* Trading steadily at 8 cents awhile back with ~55M shares and about $1M in Revs rounded-up and looking at 2017 to come in at $12-13M WITHOUT factoring in OTC Fluticare:
12M x 8 = 96 / 2 (o/s has just about doubled) = 48 cents and that is with NO Premium for anticipation of Fluticare FDA approval. So, it is LOGICAL that PPS should be approaching 50 cents soon and not fall/stay in the 20's.
On the Verge of Breaking Through:
What we Know:
- Tracking at $5M in revs for 2016(At a loss for words if they fall short)
- 3 new products being launched in 2016 (they are coming)
- Fluticare's FDA decision expected by end of Sept. (FDA, step it up)
- New Asian Deal Signed (Done deal)
- New Deal with India signed / KLABs contracted (Done Deal)
- Beyond Human Product sales Increasing YOY (Done Deal)
- Dr. Damaj is not taking actual money / pay for the rest of this year
- Enough cash on hand to fund Operations through Q3 of 2017
- Lots of warrants at an exercise price of 40 cents out there
What is Expected:
- A fair amount of short covering should FDA approval hit
- $2.5 - 3M total from recent signings of the Asian and Indian deals
- $4M/annually from those 3 new products alone
- Fluticare approval brings $13-14M in USA sales (in first Full year)
- Int'l Fluticare approval EVENTUALLY brings in $10-11M overseas
- Continued launches of existing products in more countries
- Profitability in Q2 or Q3 of 2017
- Uplisting to a better exchange
- Continued Rev growth for BH products and Vesele / cross sales
- Same or better margins (online sales have a lot nicer margins)
- Eventual buyout sometime in 2018/2019
What is Unknown:
- How does their increased exposure / customer base affect sales?
- Will they continue to make solid acquisitions?
- Will the number of and royalties from even more distribution deals happen soon?
- Will they ever do a reverse split ?
- Would Dr. Damaj ever give back some of his personal shares to the Treasury in an effort to INCREASE PPS and DECREASE O/S?
- How do they key in on & improve Marketing, inside and outside of USA ?
* Trading steadily at 8 cents awhile back with ~55M shares and about $1M in Revs rounded-up and looking at 2017 to come in at $12-13M WITHOUT factoring in OTC Fluticare:
12M x 8 = 96 / 2 (o/s has just about doubled) = 48 cents and that is with NO Premium for anticipation of Fluticare FDA approval. So, it is LOGICAL that PPS should be approaching 50 cents soon and not fall/stay in the 20's.
(1)
(0)